Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Breyanzi (lisocabtagene maraleucel)
- ublituximab
Interactions between your drugs
lisocabtagene maraleucel ublituximab
Applies to: Breyanzi (lisocabtagene maraleucel), ublituximab
Using ublituximab together with lisocabtagene maraleucel may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Let your doctor know if you develop signs and symptoms of infection such as fever, chills, sore throat, shortness of breath, blood in phlegm, weight loss; yellow skin, severe fatigue, diarrhea, vomiting, body aches; and pain or burning during urination. Also, seek immediate medical attention if you experience progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, confusion, or changes in thinking, memory, and personality, as these may be early symptoms of PML. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Columvi
Columvi is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.